Adalimumab vs. Conventional Immunosuppression for Uveitis episode artwork

EPISODE · Jan 15, 2026 · 17 MIN

Adalimumab vs. Conventional Immunosuppression for Uveitis

from Ophthalmology Journal

Dr. Edmund Tsui and author Dr. Douglas A. Jabs discuss the results of the ADVISE Trial, designed to compare adalimumab to conventional immunosuppressive drugs for the treatment of non-infectious intermediate, posterior, and panuveitides. From Dr. Jab's Ophthalmology article, "Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial." Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial. Jabs, Douglas A. et al. Ophthalmology. In press. Sign up for the next Ophthalmology Journal Virtual Club on February 25, 2026, at https://store.aao.org/ophthalmology-virtual-journal-club.html

Episode metadata supplied by the publisher feed · Published Jan 15, 2026

Embed this episode

Ready to play

Adalimumab vs. Conventional Immunosuppression for Uveitis

0:00 17:18

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Ophthalmology Journal?

This episode is 17 minutes long.

When was this Ophthalmology Journal episode published?

This episode was published on January 15, 2026.

Can I download this Ophthalmology Journal episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!